The objective of the study was to assess the cost effectiveness of oral antidiabetic therapy in type 2 diabetes mellitus in a tertiary care hospital.A prospective observational study was conducted in a population of approximately150 sample for 6 months in patients receiving antidiabetic therapy.The datas were collected using a specially designed data entry form including, patient specific HbA1C and other glycaemic values along with the prescription details of the patient with a follow up to determine the most cost- effective drug among oral hypoglycaemic agents using the Incremental Cost Effectiveness Ratio (ICER).Glimepiride was found to be the most cost-effective drug with lowest ICER of Rs 1182.273 among monotherapy.Among multiple drug therapy (1+1), Voglibose as an add on to Glimepiride while Metformin added to a fixed dose combination of Metformin and Glimepiride were found to be the most costeffective drug with the lowest ICER of Rs.2217.6 and Rs 369 respectively.Among multiple drug therapy (1+2) Voglibose and Glimepiride added on to Metformin alone and, Glibenclamide and Voglibose added on to the fixed dose combination of Metformin and Teneligliptin were found to be the most cost-effective drug with the lowest ICER of Rs 3085.71 and Rs 184.5, respectively.The most cost-effective drug among FDC was found to be Metformin + Glimepiride with the lowest ICER of Rs 1642.48.Among fixed dose triple combination of Metformin + Glimepiride + Pioglitazone was found to be dominant.Most of the patients were receiving monotherapy (41.33%) followed by FDC (34.66%).
展开▼
